A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05931-5 ↗At a glance
Fallbericht in Annals of Hematology, 2024. Written by Cristina Frusteri and 1 co-authors. Institution: Cancer Research & Cell Biology Laboratory, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy. Major MEDLINE topics: CD4-Positive T-Lymphocytes, Lymphoma, Follicular, Rituximab. 9 references.
Abstract (original language)
Bone marrow reactive T-cell infiltrates have been frequently observed in patients affected by follicular lymphoma after rituximab treatment. In some studies, bone-marrow T-cell expansion has been associated with an effective anti-tumor response and favorable prognosis. In this manuscript, we report on a particularly brisk CD4+ T-cell reaction occurring after rituximab treatment for follicular lymphoma and involving the peripheral blood in addition to the bone marrow. Peripheral blood T-cell reaction was mainly composed of effector-memory CD4+ T cells and may reflect the expansion of an effective anti-tumor immunity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cancer Research & Cell Biology Laboratory, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
- Cancer Research & Cell Biology Laboratory, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy. isacco.ferrarini@univr.it.
Cite
APA
Frusteri, C., & Ferrarini, I. (2024). A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-024-05931-5
Vancouver
Frusteri C, Ferrarini I. A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma. Annals of Hematology. 2024. doi:10.1007/s00277-024-05931-5
BibTeX
@article{Frusteri2024,
author = {Frusteri, Cristina and Ferrarini, Isacco},
title = {A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05931-5}
}
EUVIMED